Decoy Therapeutics Inc. (DCOY)

Decoy Therapeutics has secured funding to begin clinical trials for its programs targeting respiratory illnesses.

Decoy Therapeutics arranges a PIPE with $3.5M upfront and up to $17.5M in milestone warrant proceeds to fund its multi-viral antiviral programs toward clinical trials.

LRMR Stock Slides As Traders Eye Cash Runway And Volatility · SWMR Jumps As Swarmer Inc Draws Aggressive Dip Buyers · Valuation ratios are quirky here. A P/E around 0.31 and price-to-book near 0.83 do not mean DCOY is “cheap” in a classic sense; they mostly reflect tiny earnings relative ...

On the other side of the ledger, total liabilities sit around $4.5M, leaving stockholders’ equity close to $3.9M. That gives DCOY a price‑to‑book ratio of roughly 0.8, which tells traders the market is valuing the company below its stated net assets. Anterix ATEX Jumps As Earnings Beat And ...

Decoy Therapeutics shares are surging Monday after a $21 million private placement financing with a healthcare investor at $5.91 per share.